Novartis (NVS)
(Real Time Quote from BATS)
$114.22 USD
+0.27 (0.24%)
Updated Oct 7, 2024 01:14 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Price, Consensus and EPS Surprise
NVS 114.22 +0.27(0.24%)
Will NVS be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for NVS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVS
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
NVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Here's Why You Should Add ALNY Stock to Your Portfolio Right Now
Other News for NVS
Novartis a Top Ranked SAFE Dividend Stock With 3.3% Yield (NVS)
Jazz Pharmaceuticals: Unveiling Growth Potential From Non-Small Cell Lung Cancer Market
Trump backs off support of controversial drug pricing plan, STAT reports
BNY Mellon International Equity Fund Q2 2024 Commentary
U.S. tweaks 2025 Medicare price negotiation process